UAE performs first robotic surgery with HIPEC
Cleveland Clinic Abu Dhabi has successfully performed the UAE's first robotic cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) to treat a rare appendiceal tumour, in a medical milestone that reinforces Abu Dhabi's position as a global destination for innovative healthcare.
The complex procedure, performed on a 48-year-old patient, involved the removal of multiple internal organs to prevent the spread of the tumour in her abdomen.
This groundbreaking procedure was led by Dr Yasir Akmal, Staff Physician in the Digestive Disease Institute at Cleveland Clinic Abu Dhabi and an American Fellowship-trained surgical oncologist, and a multi-disciplinary team.
Appendiceal tumours account for less than 1 per cent of malignancies worldwide and are found in approximately 1.4 per cent of patients who undergo an appendectomy.
The patient initially presented symptoms resembling appendicitis, leading to the removal of her appendix.
However, during the procedure, her surgeon discovered gelatinous deposits, a jelly-like substance, in the abdominal cavity.
A subsequent pathology report confirmed the presence of a rare low-grade mucinous neoplasm, a tumour that, if untreated, could spread throughout the abdomen and result in a condition known as pseudomyxoma peritonei or 'jelly belly.'
Dr Georges-Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi, said, 'We are pushing the boundaries of robotic surgery and are proud to have used such an advanced technology for a complex procedure like Paola's. Cleveland Clinic Abu Dhabi is a leader in surgical innovation, continuously refining minimally invasive techniques to improve outcomes and enhance quality of life.'
Following the tumour removal, HIPEC treatment (Hyperthermic Intraperitoneal Chemotherapy) was administered- a technique where heated chemotherapy (42 degrees Celsius) is circulated within the abdominal cavity for 90 minutes to eliminate any residual cancer cells.
Highlighting both the preventive and curative nature of the surgery, Dr Akmal said that the patient's condition was diagnosed at an advanced but treatable stage, and thanks to the timely intervention of the multidisciplinary team, supported by specialised AI-driven diagnostic tools, the team was able to navigate the process of eliminating the cancer cells in her body with precision.
WAM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The National
6 hours ago
- The National
Emirati man with rare blood disorder benefits from new $2 million gene therapy in the US
An Emirati man with a rare inherited disorder has become only the second patient in the world to benefit from a pioneering $2 million gene therapy that eliminates the need for regular blood transfusions. Khalifa Dawood, 22, from Abu Dhabi said he has been given a 'new lease on life' as he recovers from the novel gene treatment he received at Cleveland Clinic Children's hospital in Ohio, which recently won medical approval for the therapy. The UAE has some of the regions highest rates of thalassaemia, also known as sickle cell disease, a condition that limits the body's ability to produce healthy red blood cells. While some carriers show very limited symptoms, others experience bone deformities, shortness of breath, dizziness, organ damage and heart palpitations. The condition can require regular blood transfusions, with research suggesting thalassaemia affects as many as 16.5 per cent of the population. A new treatment used for the first time by the Cleveland Clinic Children's hospital has proven to modify a patient's blood forming cells, and can be delivered as a one-time treatment called Casgevy. Mr Dawood said that he hoped the treatment would allow him to lead a normal life, without the need for regular hospital stays. 'I am hoping this gives me a new lease on life where I am energised to enjoy it,' he said. Life-changing treatment Since its approval by the US Food and Drug Administration in January, the therapy has been delivered to an American woman from Ohio and Mr Dawood. I am hoping this gives me a new lease on life where I am energised to enjoy it Khalifa Dawood Although the treatment is expensive, it is life changing for those who receive it, according to Dr Rabi Hanna, chairman of the paediatric haematology-oncology department at Cleveland Clinic Children's hospital. It is not uncommon for adults to receive specialist care at a children's centre, particularly for conditions they have had since birth, as is the case with Mr Dawood. 'Unlike regular medicines that people take for years, Casgevy is meant to be a one-time treatment that could last a lifetime,' he said. 'It uses CRISPR gene editing, which is a very advanced science. Editing cells safely and precisely takes a lot of time, technology, and testing. 'It is also custom-made, as Casgevy is made from a person's own cells, which are collected, sent to a lab, edited and then returned. That process is complex and individualised.' The innovative treatment uses a gene editing technology called CRISPR/Cas9 to modify a patient's stem cells. The edited cells are then transplanted back into the patient, where they produce more haemoglobin in new healthy red blood cells. The FDA's approval was based on results from a single arm which showed 91 per cent of patients with beta thalassaemia did not need a blood transfusion for at least a year after having the treatment. Costly medical care Despite the therapy's success, it is likely to remain out of reach for the majority with costs of about $2.2 million. Gene therapies are typically the most expensive medical treatments. Etranacogene dezaparvovec, sold under the brand name Hemgenix is a gene therapy used for the treatment of haemophilia B, a potentially life threatening disorder that prevents blood from clotting. Priced at about $3.5 million, it was the world's most expensive drug until the arrival of Lenmeldy in March last year. The gene treatment developed by Orchard Therapeutics costs about $4.2 million and is used to treat life threatening nerve disorders in young children. High costs of certain drugs can be covered by insurers, government health systems or charitable foundations when there are no other treatment options. Drug companies also occasionally offer financial support programmes for families in need. The process of administering Casgevy begins by collecting stem cells from the patient's blood that are then sent to the lab to be edited using tiny, precise scissors. By clipping off the DNA responsible for preventing the body making healthy haemoglobin, the repaired cells can then be returned to the body. A course of chemotherapy is then required to clear out the old, sick marrow cells, allowing new healthy ones to grow in their place. Recovery time in the hospital is about four weeks. As the science behind gene editing improves, it should become faster, easier and cheaper to edit cells with higher accuracy, and fewer side effects. 'It is my hope and prediction that price will come down, but I am not sure how quickly,' said Dr Hanna. 'As the science of gene editing improves, it may become faster, easier, and cheaper to edit cells with higher accuracy and fewer side effects. 'Right now, Casgevy is the first gene editing therapy approved for sickle cell and thalassaemia. 'But more companies are developing similar treatments. When that happens, competition can help drive prices down. 'Also as companies learn how to make these therapies at scale, they may reduce production and delivery costs. 'Think of it like early computers or smartphones – they were expensive at first, but prices dropped as technology improved.' Global health drive Although patients like Mr Dawood must travel overseas for expensive gene therapy, the Gulf is also emerging as a go-to destination for emerging treatments. The King Faisal Specialist Hospital & Research Centre in Saudi Arabia is emerging as a leader of regional clinical trials and delivered a breakthrough in haemophilia care, using one-time gene therapy to restore clotting function in eight patients. In the UAE, at Medcare Royal Speciality Hospital Al Qusais, patients are receiving the latest care for rare genetic disorders like spinal muscular atrophy and Duchenne muscular dystrophy, two life-limiting growth conditions. Doctors there said patients were travelling into Dubai from Turkey and elsewhere in the region. Medcare Women and Children Hospital was one of the first private clinics outside the US to administer gene therapy for spinal muscular atrophy, and has since delivered 100 infusions. American Hospital, Al Jalila Children's Hospital and Fakeeh University Hospital also offer gene therapy Zolgensma, which can cost about $2 million per dose. Dr Vivek Mundada, a consultant paediatric neurologist at Medcare Royal Speciality Hospital, said the drug had delivered remarkable outcomes in managing complex genetic conditions. 'Dubai is becoming a centre of medical innovation, and Medcare is proud to be leading that movement, especially in the field of rare genetic diseases,' he said. 'Through our comprehensive, patient-centred care model, we are transforming outcomes for children who previously had limited treatment options.'
Zawya
8 hours ago
- Zawya
PolyU startups showcase innovation and entrepreneurial achievements at London Tech Week 2025
HONG KONG SAR - Media OutReach Newswire - 12 June 2025 - The Hong Kong Polytechnic University (PolyU) took part in the world-renowned London Tech Week 2025 held from 9 to 11 June in London, UK, as the only participating university from Hong Kong. Four PolyU startups showcased their ground-breaking innovations in artificial intelligence (AI), advanced manufacturing technologies and healthcare solutions. The event attracted business leaders, industry experts and investors from around the world, providing the PolyU startups with valuable opportunities to explore potential collaborations and establish partnerships. PolyU is committed to translating cutting-edge research into impactful solutions that address real-world challenges. Below are introductions to the four PolyU startups. PolyU Startup Founder(s) Introduction Advantage Data Vision Limited Prof. Lawrence Wing Chi CHAN Associate Professor, Department of Health Technology and Informatics; and Director, Advantage Data Vision Limited The startup has leveraged massive real‑world, multi‑omics datasets and patented AI algorithms to create a cloud‑based platform that accurately predicts patients' response to cancer immunotherapy. The deep‑learning engine guides clinicians, optimises hospital resources, reduces adverse events and accelerates pharmaceutical trials through precise patient stratification and risk assessment, delivering tangible value worldwide. Light-weight Technologies Limited Prof. Jianguo LIN Chair Professor of Materials Technologies, Department of Industrial and Systems Engineering; and Co-founder and Chairman, Light-weight Technologies Limited Dr Qingsong WENG Research Associate, Department of Industrial and Systems Engineering; and Co-founder and Chief Executive Officer, Light-weight Technologies Limited The startup uses their globally unique light alloy manufacturing technologies, such as advanced hot stamping and extrusion techniques, with its self-developed smart industrial software and advanced simulation platform to produce ultra-thin, ultra-wide light alloy profiles and complex curved profiles that are unattainable with existing manufacturing processes. The startup provides high-strength, lightweight, cost-effective, and sustainable solutions that enable energy saving and emission reduction for the automotive, aerospace, railway, marine, and other engineering sectors, gaining wide recognition from leading global OEMs. UbiquiTech Innovations Limited Prof. Jiannong CAO Dean, Graduate School; Otto Poon Charitable Foundation Professor in Data Science; Chair Professor of Distributed and Mobile Computing; Director, Research Institute for Artificial Intelligence of Things; Director, University Research Facility in Big Data Analytics; and Co-founder and Chief Scientist, UbiquiTech Innovations Limited Dr Zhixuan LIANG PolyU GBA Postdoctoral Fellow; and Chief Executive Officer, UbiquiTech Innovations Limited The startup is committed to the intersection of robotics, AI and smart city solutions, with a view to developing cutting-edge autonomous robots designed to address complex challenges in modern urban and industrial environments. viAct Mr Gary Chun-kui NG Co-founder and Chief Executive Officer, viAct Mr Hugo CHEUK Co-founder and Chief Operating Officer, viAct viAct is a pioneer in AI monitoring technology dedicated to enhancing safety and efficiency in heavy industries such as construction, oil and gas, and manufacturing. The startup made it onto Forbes Asia 100 to Watch list in 2022. Its leading, globally deployed technology "Scenario-based Vision Intelligence", was showcased at renowned international events such as the World Economic Forum. At the event's panel discussion themed "Creating the Future from Campus: Why are University Spinouts so Important for Innovation?", Prof. Christopher CHAO, PolyU Vice President (Research and Innovation), shared his insights into knowledge transfer, the nurturing of university spinouts, and the support and resources available to PolyU startups. Prof. Chao remarked, "Supported by PolyU's signature startup ecosystem, PolyVentures, our startups are spearheading translational innovations that generate long-lasting global societal impact. Our ecosystem not only provides invaluable development opportunities but also fosters the international growth of our entrepreneurs. I am delighted to see PolyU startups shine at London Tech Week, inspiring global audiences with their creativity and determination to make a difference." This year, the London Tech Week attracted over 45,000 participants from more than 90 countries, including startups, technology giants, investors and innovators. The event provided a platform for startups to engage in person with venture capitalists, corporate investors and angel investors; promote their solutions on dedicated stages; connect with industry leaders at the forefront of innovation; and gain valuable insights from successful entrepreneurs who have expanded globally. For more information, please visit the event website. Hashtag: #PolyU The issuer is solely responsible for the content of this announcement. PolyU
Al Etihad
a day ago
- Al Etihad
World sees second-warmest May on record
11 June 2025 14:02 BERLIN (dpa)May 2025 was the second-hottest May on record worldwide, with a global average temperature of 15.79 degrees Celsius, just 0.12 degrees below the record set in May 2024, according to the EU's Copernicus Climate Change temperature was 1.4 degrees Celsius above the estimated pre-industrial average for 1850-1900, the Bonn-based agency said on of north-west Europe experienced an exceptionally dry spring, including March, April and May with the lowest rainfall and soil moisture levels since at least Climate Change Service regularly publishes data on surface temperatures, sea ice cover and findings are based on computer-generated analyses of measurements from satellites, ships, aircraft and weather stations worldwide. Much of the data dates back to 1950, with some records reaching further back.
